ADC Therapeutics SA (ADCT)
USD 1.91
(-10.33%)
USD 1.91
(-10.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -146.76 Million USD | -47.49% |
| 2022 | -108.05 Million USD | 57.61% |
| 2021 | -223.71 Million USD | 2.14% |
| 2020 | -219.26 Million USD | -109.3% |
| 2019 | -114.1 Million USD | 9.22% |
| 2018 | -122.35 Million USD | -36.09% |
| 2017 | -91.32 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -32.77 Million USD | -21.14% |
| 2024 Q2 | -28.2 Million USD | 31.07% |
| 2023 Q2 | -37.11 Million USD | 23.51% |
| 2023 Q3 | -34.19 Million USD | 7.87% |
| 2023 Q1 | -48.52 Million USD | -367.22% |
| 2023 FY | - USD | -47.49% |
| 2023 Q4 | -25.36 Million USD | 25.82% |
| 2022 Q4 | -10.38 Million USD | -239.62% |
| 2022 Q3 | 7.43 Million USD | 110.54% |
| 2022 Q2 | -70.61 Million USD | -194.76% |
| 2022 FY | - USD | 57.61% |
| 2022 Q1 | -23.95 Million USD | 48.85% |
| 2021 FY | - USD | 2.14% |
| 2021 Q3 | -66.47 Million USD | 3.52% |
| 2021 Q1 | -49.23 Million USD | 7.78% |
| 2021 Q4 | -46.83 Million USD | 29.55% |
| 2021 Q2 | -68.89 Million USD | -39.93% |
| 2020 Q1 | -42.92 Million USD | -23.35% |
| 2020 FY | - USD | -109.3% |
| 2020 Q2 | -125.01 Million USD | -191.28% |
| 2020 Q3 | -17.76 Million USD | 85.79% |
| 2020 Q4 | -53.39 Million USD | -200.57% |
| 2019 Q4 | -34.79 Million USD | -14.73% |
| 2019 Q3 | -30.32 Million USD | -30.56% |
| 2019 Q2 | -23.22 Million USD | 8.11% |
| 2019 Q1 | -25.27 Million USD | 18.06% |
| 2019 FY | - USD | 9.22% |
| 2018 Q3 | -31.1 Million USD | 1.31% |
| 2018 Q2 | -31.51 Million USD | 0.0% |
| 2018 FY | - USD | -36.09% |
| 2018 Q1 | -31.51 Million USD | 0.0% |
| 2018 Q4 | -30.84 Million USD | 0.81% |
| 2017 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alto Neuroscience, Inc. | -34.56 Million USD | -324.634% |
| Annovis Bio, Inc. | -45.03 Million USD | -225.884% |
| Biohaven Pharmaceutical Holding Company Ltd. | -429.13 Million USD | 65.801% |
| Ginkgo Bioworks Holdings, Inc. | -821.29 Million USD | 82.13% |
| Nuvation Bio Inc. | -99.6 Million USD | -47.351% |
| Nuvation Bio Inc. | -99.6 Million USD | -47.351% |
| Arcus Biosciences, Inc. | -283 Million USD | 48.141% |
| Theriva Biologics, Inc. | -19.85 Million USD | -639.206% |
| Zymeworks Inc. | -129.95 Million USD | -12.932% |